Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials-Reference-Cited by-同舟云学术

Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials

Published:2020-06-01 Issue:2 Volume:19 Page:759-765
ISSN:2251-6581
Container-title:Journal of Diabetes & Metabolic Disorders
language:en
Short-container-title:J Diabetes Metab Disord

Author:

Cordero Alberto,Rodríguez-Mañero Moisés,Fácila Lorenzo,Fernández-Olmo M. Rosa,Gómez-Martínez Manuel J.,Valle Alfonso,Castellano Jose Mª,Toro Miriam Martín,Seijas-Amigo José,Vicedo Alvaro,González-Juanatey José R.

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40200-020-00557-6.pdf

Reference39 articles.

1. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–72. https://doi.org/10.1093/eurheartj/ehx144.

2. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285–350. https://doi.org/10.1016/j.jacc.2018.11.003.

3. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111–88. https://doi.org/10.1093/eurheartj/ehz455.

4. Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, et al. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70(14):1785–822. https://doi.org/10.1016/j.jacc.2017.07.745.

5. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500–9. https://doi.org/10.1056/NEJMoa1500858.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records;PLOS ONE;2024-08-22

2. Global trends and research hotspots of PCSK9 and cardiovascular disease: a bibliometric and visual analysis;Frontiers in Cardiovascular Medicine;2024-06-03

3. Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary syndrome: A systematic review and meta-analysis;Medicine;2024-05-31

4. The benefits of PCSK9 inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis;Emergency and Critical Care Medicine;2024-02-29

5. Role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in diabetic complications;Canadian Journal of Physiology and Pharmacology;2024-01-01